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Quick guide
p53 tumour suppressor
Also known as¼ the p53 oncogene
(that was before the early 1990s,
when it was realized that the ability
to induce tumours was an attribute of
a mutant form of p53, not the
wild-type); the “Guardian of the
Genome”; the p53 transcriptional
activator, the p53 checkpoint control
protein, the p53 apoptosis inducer…
or just plain old p53.
It first came to prominence¼ as a
‘tumour antigen’ in the early 1980s,
as an oncogene in the mid-1980s, and
as a tumour suppressor in this decade.
Its heyday was¼ perhaps 1993, when
it became Science’s ‘Molecule of the
Year’. But it was certainly on the tips
of many tongues again a year or two
ago with the identification of its
partner, MDM2, its interaction with
cell-cycle control proteins, and the
publication of the crystal structure.
Not to be confused with¼ p35, the
baculovirus-encoded apoptosis
inhibitor, p52, p54, or any other
‘p number’ protein.
Its known functions are¼ as a tumour
suppressor — it arrests growth and
can induce apoptosis; as both a
transcriptional activator and a
repressor; as a mediator of cell-cycle
responses to DNA damage (see
Figure). So perhaps it’s just as well it
wasn’t given a more descriptive
name early in its career.
Other speculated functions include¼
does it really need more? Well, it
seems to function in multicellular
development and differentiation, too,
and there’s some evidence that it’s an
exonuclease. If you’re beginning to
think that researchers from all areas
of biology are obsessed with p53,
witness the number of grant
applications claiming that studies of
p53 will provide a cure for cancer,
explaining the cell cycle, DNA repair
and morphogenesis along the way.
Who are its known associates? MDM2
is a definite, being involved in p53
transcriptional responses and in the
ubiquitin-mediated degradation of
p53. There are numerous proteins for
which in vitro interactions with p53
are claimed — including kinases and
co-regulators — though in most cases
the evidence is controversial.
Most likely to be mentioned by¼
someone at almost every conference
you attend, but always in talks by
David Lane, Arnold Levine,
Geoffrey Wahl, Karen Vousden,
Carol Prives and Moshe Oren, and
usually by Bert Vogelstein.
So is there a mountain of publications
on p53? At the last count, there were
11,226 papers that mention p53,
according to Medline.
Does it have commercial potential? A
lot of people think so. The loss or
malfunction of p53 is thought to
contribute to the development of
half of all cancers, so there’s great
interest in designing drugs to restore
or enhance its activity.
Don’t say¼ “Didn’t it used to be an
oncogene?”, or “If it’s so crucial, how
come p53 knockout mice live to a
ripe old age? And how do flies and
worms survive without it?”
Do say¼ “p53 is crucial to
understanding metazoan life.”
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An overview of the biochemical and cellular
effects of p53. These differ between cell
types, depending on the absolute levels of
p53, its post-translational modification (for
example, by phosphate) and the range of
associated molecules with which it interacts.
(Adapted from an original by Peter Hall,
University of Dundee, UK.)
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